WO2014180882A3 - Traitement des métastases cérébrales d'un cancer - Google Patents

Traitement des métastases cérébrales d'un cancer Download PDF

Info

Publication number
WO2014180882A3
WO2014180882A3 PCT/EP2014/059303 EP2014059303W WO2014180882A3 WO 2014180882 A3 WO2014180882 A3 WO 2014180882A3 EP 2014059303 W EP2014059303 W EP 2014059303W WO 2014180882 A3 WO2014180882 A3 WO 2014180882A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
brain metastasis
treatment
metastasis
brain
Prior art date
Application number
PCT/EP2014/059303
Other languages
English (en)
Other versions
WO2014180882A2 (fr
Inventor
Angels SIERRA JIMÉNEZ
Baldomero Oliva Miguel
Laia MUIXÍ
Original Assignee
Universitat De Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Barcelona filed Critical Universitat De Barcelona
Publication of WO2014180882A2 publication Critical patent/WO2014180882A2/fr
Publication of WO2014180882A3 publication Critical patent/WO2014180882A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés de formule (I), d'inhibiteurs de GRP94 et d'inhibiteurs d'HDAC dans le traitement d'une métastase cérébrale d'un cancer, de préférence une métastase cérébrale d'un cancer du sein ou une métastase cérébrale d'un cancer du poumon.
PCT/EP2014/059303 2013-05-07 2014-05-07 Traitement des métastases cérébrales d'un cancer WO2014180882A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361820444P 2013-05-07 2013-05-07
EP13382168.6 2013-05-07
EP13382168 2013-05-07
US61/820,444 2013-05-07

Publications (2)

Publication Number Publication Date
WO2014180882A2 WO2014180882A2 (fr) 2014-11-13
WO2014180882A3 true WO2014180882A3 (fr) 2015-01-08

Family

ID=48236835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/059303 WO2014180882A2 (fr) 2013-05-07 2014-05-07 Traitement des métastases cérébrales d'un cancer

Country Status (1)

Country Link
WO (1) WO2014180882A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015341301B2 (en) 2014-10-30 2019-05-16 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
AU2019381688A1 (en) 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087307A2 (fr) * 2000-05-15 2001-11-22 Celgene Corp. Compositions et methodes de traitement du cancer
WO2005046593A2 (fr) * 2003-11-06 2005-05-26 Celgene Corporation Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087307A2 (fr) * 2000-05-15 2001-11-22 Celgene Corp. Compositions et methodes de traitement du cancer
WO2005046593A2 (fr) * 2003-11-06 2005-05-26 Celgene Corporation Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"1200 POSTER Phase II study of thalidomide in patients with brain metastases from malignant melanoma", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 3, no. 2, 1 October 2005 (2005-10-01), pages 347, XP027684237, ISSN: 1359-6349, [retrieved on 20051001] *
ADAM S. DUERFELDT ET AL: "Development of a Grp94 inhibitor", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 134, no. 23, 13 June 2012 (2012-06-13), pages 9796 - 9804, XP055128967, ISSN: 0002-7863, DOI: 10.1021/ja303477g *
BARTLETT J B ET AL: "Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers", BRITISH JOURNAL OF CANCER, vol. 90, no. 5, 8 March 2004 (2004-03-08), pages 955 - 961, XP002727210, ISSN: 0007-0920 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 2005 (2005-10-01), HADA MASATO ET AL: "[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].", XP002727211, Database accession no. NLM16223182 *
KARIN OECHSLE ET AL: "Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER, BERLIN, DE, vol. 136, no. 1, 16 September 2009 (2009-09-16), pages 165 - 167, XP019760639, ISSN: 1432-1335 *
KNISELY J P S ET AL: "A Phase III Study of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy for Multiple Brain Metastases (RTOG 0118)", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 71, no. 1, 1 May 2008 (2008-05-01), pages 79 - 86, XP022606146, ISSN: 0360-3016, [retrieved on 20071231], DOI: 10.1016/J.IJROBP.2007.09.016 *
VESTERMARK LENE W ET AL: "A phase II study of thalidomide in patients with brain metastases from malignant melanoma.", ACTA ONCOLOGICA (STOCKHOLM, SWEDEN) 2008, vol. 47, no. 8, 2008, pages 1526 - 1530, XP002727209, ISSN: 1651-226X *

Also Published As

Publication number Publication date
WO2014180882A2 (fr) 2014-11-13

Similar Documents

Publication Publication Date Title
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
HK1219486A1 (zh) 用於治療癌症的涉及抗密蛋白 的抗體的療法
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
WO2015024876A3 (fr) Procédé de criblage
WO2015054642A3 (fr) Utilisation d'inhibiteurs du bromodomaine de cbp/ep300 pour l'immunothérapie du cancer
WO2015003816A3 (fr) Cystobactamides
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
WO2015123449A3 (fr) Compositions et procédés d'utilisation d'inhibiteurs de micro-arn
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EP3089745A4 (fr) Composés, compositions et méthodes de traitement de cancers
EP3044321A4 (fr) Nouveau marqueur pour la classification, le diagnostic et le traitement de la scoliose
RS63738B1 (sr) Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera
WO2014180882A3 (fr) Traitement des métastases cérébrales d'un cancer
IL261984B (en) Sultiame for the treatment of sleep apnea
EP2994156A4 (fr) Composés, compositions et procédés permettant le traitement des maladies par inhibition de l'activité de tgf-
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
WO2014201387A3 (fr) Méthodes d'amélioration de la santé reproductive et respiratoire
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
LV14779A (lv) 4-Amino-2-(1,2,3-triazol-1-il)-hinazolīna atvasinājumi un to sintēzes paņēmiens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14727414

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14727414

Country of ref document: EP

Kind code of ref document: A2